IPCA Laboratories

IPCA Laboratories Rule of 40

The Rule of 40 of IPCA Laboratories (IPCALAB.NS) as of Nov 17, 2026 is 24.02 %. In the previous year, Rule of 40 was 28.24 % — a change of -14.96% (lower).

Rule of 40

24.02 %

YoY

-14.96%

Last updated:

Rule of 40 of IPCA Laboratories is 2026 24.02 % . Rule of 40 of IPCA Laboratories was 2025 28.24 % . It decreases by -14.96% lower compared to the previous year.

The IPCA Laboratories Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2019
28.99 INR
Jan 1, 2020
38.54 INR
Jan 1, 2021
40.50 INR
Jan 1, 2022
25.72 INR
Jan 1, 2023
18.31 INR
Jan 1, 2024
33.20 INR
Jan 1, 2025
28.24 INR
Jan 1, 2026
24.02 INR
The IPCA Laboratories Rule of 40 history
YEARRule of 40YoY
24.02 %-14.96%
28.24 %-14.93%
33.20 %+81.28%
18.31 %-28.78%
25.72 %-36.51%
40.50 %+5.09%
38.54 %+32.96%
28.99 %+168.00%
10.82 %-41.74%
18.56 %-1,143.40%
-1.78 %-125.12%
7.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Rule of 40 of IPCA Laboratories is 24.02 % in 2026.

On Eulerpool you can find the complete historical development of Rule of 40 IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — IPCA Laboratories

All Key Metrics — IPCA Laboratories